



30 April 2020

Sydney, Australia

## **Nyrada Preclinical Program & Corporate Update Presentation**

Sydney, 30 April 2020: Nyrada, Inc (ASX: NYR) provides to shareholders and the market the slide presentation for today's global virtual investor event.

CEO, James Bonnar and Non-Executive Chairman, John Moore will discuss recent progress with the Company's two lead preclinical programs in Cholesterol-Lowering and Brain Injury, and provide a corporate update.

Investors are invited to join the webinar via the details below.

### **Webinar Details**

The details for the webinar are as follows:

Date & Time: Thursday 30 April 2020, 11:00am Australian Eastern Standard Time /  
Wednesday 29 April 2020, 9:00pm US Eastern Daylight Time

Register: Interested parties can register via a link to the webcast on the Company's website or via the following link: [Nyrada Virtual Investor Event](#)

A replay of the webcast will also be available at: [www.nyrada.com](http://www.nyrada.com) following the event.

-ENDS-

### **About Nyrada Inc**

Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological and inflammatory diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

*Authorised by Mr John Moore, Non-Executive Chairman, on behalf of the Board*

#### **Investor & Corporate Enquiries:**

Prue Kelly  
T: 0459 022 445  
E: [info@nyrada.com](mailto:info@nyrada.com)

#### **Company Secretary:**

David Franks  
T: 02 8072 1400  
E: [David.Franks@atomicgroup.com.au](mailto:David.Franks@atomicgroup.com.au)

#### **Media Enquiries:**

Catherine Strong  
Citadel-MAGNUS  
T: 02 8234 0111  
E: [cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)



### **Forward Looking Statements**

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Nyrada about circumstances and events that have not yet taken place. Although Nyrada believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.



# Improving Lives, Offering Hope

*Developing New Therapies for  
Cardiovascular & Neurological Disorders*

**Nyrada Virtual Investor Event  
April 30, 2020**

**ASX:NYR**



# Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

# Presenters



**Mr John Moore**  
**Non-Executive Chairman**



**Mr James Bonnar**  
**Chief Executive Officer**

# Nyrada Summary

## Newly listed drug discoverer and early stage developer

Diverse product portfolio with significant therapeutic and commercial potential, with near term milestones.

Cholesterol lowering (PCSK9 inhibitors) program to help up to 70% of patients taking statin drugs, currently a market worth approximately US\$19 billion.

Brain injury neuroprotectant program to help the more than 2.8 million people in the US who sustain a brain injury and 800,000 who suffer a stroke.

High calibre Board and Scientific Advisory Board, including highly connected industry and research experts in the US, Europe, Japan and Australia.

Well-funded to move programs into the clinic having raised \$8.5m at IPO, with \$6.1m cash in bank.

Commercial business model focused on maximising the value of early stage product candidates.



# Board of Directors



**Mr John Moore**  
Non-Executive  
Chairman



**Dr Graham Kelly**  
Non-Executive  
Director



**Christopher Cox**  
Non- Executive  
Director



**Mr Peter Marks**  
Non- Executive  
Director



**Mr Marcus Frampton**  
Non- Executive  
Director




**Dr Rüdiger Weseloh**  
Non- Executive  
Director

- 📌 **Nyrada operates under the direction of a board of international calibre**
- 📌 **Track record in founding and realising the value of biotech companies**



# Strategy & Business Model



Cardiovascular



Neurology






# Cholesterol and Cardiovascular Disease

Nyrada  
inc

## 1 in 4 Deaths attributed to Cardiovascular Disease

- Tobacco use
- High blood pressure
- **High cholesterol**

# High Cholesterol: The Problem



# Cholesterol Problem (US)

**62.6 million**

Total US adults with  
elevated LDL-C

**19.4 million**

Unable to achieve  
LDL-C target despite  
taking statin therapy

**27.4 million**

US adults with elevated  
LDL-C are taking a statin

# Cholesterol-Lowering Treatment Options



Low cost generics available  
US\$16 per 100 pills



Effective, combined with statin



Launched March 2020  
US\$3,600 per year



Suboptimal efficacy standalone  
Side effects



Expensive US\$5,800 per year  
Inconvenient (2-4 weekly injection)



Developed for use with a statin  
Modest LDL-C reduction over  
statin alone

**US\$19B global cholesterol-lowering drugs market in 2017 (CAGR 4.9%)<sup>1</sup>**

<sup>1</sup> Visiongain Market Research - Global Cholesterol-Lowering Drugs Market 2017-2027: Statins and Fixed-Dose Combinations, Cholesterol Absorption Inhibitors, Ion Exchange Resins, Fibrates, PCSK9 Inhibitors, Novel Drugs.


# Nyrada Cholesterol-Lowering Solution

Nyrada  
inc

Blocks action of PCSK9  
on cholesterol receptor

Statins increase  
PCSK9 levels

High PCSK9 =  
high LDL cholesterol



Small molecule PCSK9 inhibitor  
overcomes longstanding challenge  
of an oral PCSK9 treatment

# What is Unique?

Single pill  
treatment

Convenient  
for patient

Cost-  
effective



# Cholesterol Drug Market (Non-Statin)

## Injectable

Evolocumab (Repatha)	Marketed	Amgen	PCSK9 inhibitor	Monoclonal
Alirocumab (Praluent)	Marketed	Sanofi/Regeneron	PCSK9 inhibitor	Monoclonal
Inclisiran	Phase III	The Medicines Company / Novartis	PCSK9 siRNA	siRNA
Evinacumab	Phase III	Regeneron	ANGPTL3 inhibitor	Monoclonal
LY3015014	Phase II	Lilly	PCSK9 inhibitor	Monoclonal
AFFITOPE (AT04A)	Phase I	AFFiRiS AG	PCSK9	Vaccine

## Oral

Bempedoic acid (Nexletol)	Marketed	Esperion	ATP citrate lyase inhibitor	Small molecule
P-21	Preclinical	Shifa Biomedical	PCSK9 inhibitor	Small molecule
NYX-330	Preclinical	Nyrada Inc.	PCSK9 inhibitor	Small molecule

Very little new competition for a new oral medication



# Brain Injury Problem


## Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke

Neurology / physical rehabilitation only existing therapies


- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI

- High mortality
- Severe life-long disability
- High ongoing healthcare cost




*Minutes*

**Initial injury size**



*Hours*







*Days*

**Final injury size**

# Potential Effects of Brain Injury

May lead to short- or long-term issues affecting:

-  **Cognitive Function**
  - attention and memory
-  **Motor function**
  - extremity weakness, impaired coordination and balance
-  **Sensation**
  - hearing, vision, impaired perception and touch
-  **Behaviour**
  - emotional regulation, depression, anxiety, aggression, impairments in behavioural control, personality changes




# Nyrada Brain Injury Solution




## Treatment for secondary brain injury following Stroke or TBI

- Prevent cell death
- Attenuate damaged brain volume
- Improve survivability, limit disability, improve quality of life



# Brain Injury Drug Market

■ Hospital admissions each year (US)    ■ Patients who present within 12 hour window



**700,000**  
**patients**

Annual US market size for  
brain injury combined  
(approx.)

**US\$20B global severe TBI treatment market in 2024 (CAGR 5%)<sup>1</sup>**

<sup>1</sup> Energias Market Research, Global Traumatic Brain Injuries Treatment Market Outlook, Trend and Opportunity Analysis, Competitive Insights, Actionable Segmentation & Forecast 2024

# Program Status

Proof-of-concept  
established



Lead optimisation well  
advanced



First-in-human studies  
(Phase I)

- Cholesterol-lowering:  
**late-2021**
- Neuroprotection:  
**mid-2022**



# Scientific Advisory Board



**Prof Gary Housley**  
MSc PhD



**Prof Junichi Nabekura**  
PhD



**Prof David Burke**  
MD DSc AC



**Prof Gilles Lambert**  
PhD



**Jim Palmer**  
PhD

 **International team of experts with vast experience in drug development**

# Key Metrics & News Flow

Market capitalisation  
(as at 29 April 2020) **\$20M**

Share price  
(as at 29 April 2020) **\$0.18**

CDIs free float **76,072,869**

CDIs 12 months escrow **205,000**

CDIs 24 months escrow **33,105,853**

Cash at bank (31 Mar 2020) **A\$6.1m**

ASX listing **January 16, 2020**

H2 2020	H1 2021	H2 2021	H1 2022
------------	------------	------------	------------

Lead product candidate selection for  
cholesterol program: ▲

Lead product candidate selection for  
neuroprotectant program: ▲

Cholesterol-lowering program  
to enter clinic: ▲

Neuroprotection program  
to enter clinic: ▲




Further preclinical results: **ongoing**

Potential industry collaborations / non-dilutive funding: **ongoing**



# Summary

- 📌 **Diverse portfolio**
- 📌 **Large, under-served therapeutic areas**
- 📌 **Compelling proof of concept data**
- 📌 **Commercial business model**
- 📌 **Right team and well-funded to execute**




# Discover More & Follow Us



Neuroprotection  
Animation



Cholesterol-Lowering  
Animation



Recent PCSK9i  
Publication



@nyrada\_inc



@nyrada\_inc

[www.nyrada.com](http://www.nyrada.com)

